Heather Favazza was named Chief Accounting Officer of OptimizeRx Corp, effective January 1, 2027. As of November 6, 2026, OptimizeRx Corp has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 9, 2026 to August 12, 2026, naming 1 appointment and 1 departure (Form 8-K, August 12, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like OptimizeRx Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Edward Stelmakh · Effective: 2026-12-31 · 8-K, 2026-08-12
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-05
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-09
OptimizeRx Corp reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-09 to 2026-08-12. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as OptimizeRx Corp files it.
Also on the record for OptimizeRx Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 21, 2026 | Stake report, Schedule 13G/A, by ROYCE & ASSOCIATES LP | 6.98% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by KENNEDY CAPITAL MANAGEMENT LLC | 6.7% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.8% of the class | 5%+ stakes | Source |
| July 22, 2026 | Stake report, Schedule 13G, by ROYCE & ASSOCIATES LP | 5.81% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| October 31, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.7% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by ROYCE & ASSOCIATES LP | 4.27% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs OptimizeRx Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on OptimizeRx Corp and the records around it.
OptimizeRx Corp elsewhere on the record
Companies that share a holder
- KENNEDY CAPITAL MANAGEMENT LLC also filed stake reports on 3 other companies: Park Dental Partners, Inc. (Oct 2026), BranchOut Food Inc. (Aug 2026), AUDIOEYE INC (May 2026)
- ROYCE & ASSOCIATES LP also filed stake reports on 61 other companies: Aetherion Technoligies Inc. (Oct 2026), Andersen Group Inc (Oct 2026), NN, Inc. (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch OptimizeRx Corp
Get an email when OptimizeRx Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on OptimizeRx Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on OptimizeRx Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OptimizeRx Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-12 | Out | 2026-12-31 | 8-K, 2026-08-12 | ||
| 2026-08-12 | In | Chief Accounting Officer | 2027-01-01 | 8-K, 2026-08-12 | |
| 2026-06-05 | Reported | not named in the filing | 8-K, 2026-06-05 | ||
| 2026-04-09 | Reported | not named in the filing | 8-K, 2026-04-09 |
Who leads OptimizeRx Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Heather Favazza, appointed, effective 2027-01-01 (filed 2026-08-12).
New leaders reset buying decisions — get the Full Report on OptimizeRx Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at OptimizeRx Corp, with the record behind each one.
Find candidates like Chief Accounting Officer at OptimizeRx CorpEvery change, in the filing's words
Departing: Edward Stelmakh, effective 2026-12-31
Pursuant to the plan, Edward Stelmakh will step down as Chief Financial & Strategy Officer effective December 31, 2026.
Appointed: Heather Favazza, Chief Accounting Officer, effective 2027-01-01
Mr. Andrew D'Silva will become Chief Financial Officer and Ms. Heather Favazza will become Chief Accounting Officer, each effective January 1, 2027.
- Finance Leadership Succession Plan On August 7, 2026, the Board of Directors (the "Board") of OptimizeRx Corporation (the "Company") approved a finance leadership succession plan.
- Entry into Separation Agreement with Mr. Stelmakh In connection with Mr. Stelmakh's separation from employment with the Company, Mr. Stelmakh and the Company entered into a Separation Agreement and Release of Claims, which includes Advisory Terms & Conditions (the "Stelmakh Separation and Advisory Agreement").
- Under the terms of the Stelmakh Separation and Advisory Agreement, Mr. Stelmakh will receive: (1) continuation of his $450,000 per annum base salary for a period of 12 months; (2) a one-time lump sum payment of his annual cash bonus target of $247,500; and (3) reimbursement of COBRA premium payments for continued health, dental and vision benefit coverage for 12 months, unless earlier terminated pursuant to the terms of COBRA.
- Pursuant to the Stelmakh Separation and Advisory Agreement, Mr. Stelmakh will provide advisory services to the Company for a period of 12 months, through December 31, 2027 (the "Stelmakh Advisory Term").
- In exchange for such services, any equity previously granted to Mr. Stelmakh will continue to vest in the ordinary course during the Stelmakh Advisory Term.
- The Stelmakh Separation and Advisory Agreement also contains a release of claims provision.
Reported
Accordingly, effective as of the Separation Date, Ms. Greco will no longer serve as the Company's Chief Commercial Officer.
- As previously disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, OptimizeRx Corporation (the "Company") and Theresa Greco agreed on May 11, 2026 to a separation, effective as of June 15, 2026 (the "Separation Date").
- In connection with Ms. Greco's separation from employment with the Company, on June 1, 2026, Ms. Greco and the Company entered into a Separation Agreement and Release of Claims, which includes Advisory Terms and Conditions (the "Separation and Advisory Agreement").
- The Separation and Advisory Agreement will become effective and enforceable on June 9, 2026, provided such agreement is not revoked prior thereto.
- Pursuant to the Separation and Advisory Agreement, Ms. Greco will provide advisory services to the Company for a period of twelve (12) months, through June 15, 2027 (the "Advisory Term"), during which time any equity previously granted to Ms. Greco will continue to vest in the ordinary course.
- As Advisor, Ms. Greco's responsibilities to the Company will be to render advice as the Company and the Chief Executive Officer will determine from time to time.
- In addition, in the event of a change in control during the Advisory Term, Ms. Greco will receive a special bonus pursuant to the terms the Special Bonus Agreement by and between the Company and Ms. Greco, dated September 8, 2025.
Reported
The appointment of Ms. Varghese Presti as an independent director is in furtherance of the Company's ongoing process to refresh and expand its Board.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
- On April 3, 2026, the Board of Directors (the "Board") of OptimizeRx Corporation (the "Company"), upon the recommendation of the Board's Nominating & Governance Committee, appointed Mary Varghese Presti to serve as a director of the Company until the date of the Company's 2026 annual meeting of stockholders and until her successor is elected and qualified, except in the event of her earlier death, resignation or removal.
- In connection with Ms. Varghese Presti's appointment to the Board, the Board expanded the size of the Board to seven members from its current six members.
- The Board also appointed Ms. Varghese Presti to serve as a member of the Audit Committee.
- As a non-employee director, Ms. Varghese Presti will participate in the Company's previously disclosed non-employee director compensation program, which includes, among other things, an annual cash retainer of $45,000, an annual equity grant with a grant date value of approximately $175,000, and an additional annual cash retainer of $10,000 for serving as a member of the Audit Committee.
Tools for this story
Each opens in a new tab, filled in for OptimizeRx Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.